<DOC>
	<DOCNO>NCT02164461</DOCNO>
	<brief_summary>To evaluate tolerability safety ADXS11-001 ( 1 x 10^10 colony form unit [ cfu ] ) administer prophylactic premedication repeat 3-dose study cycle woman persistent , metastatic , recurrent squamous non-squamous carcinoma , adenosquamous , adenocarcinoma cervix . To evaluate tumor response progression-free survival ( PFS , time progression ) immune-related Response Evaluation Criteria Solid Tumors ( irRECIST ) .</brief_summary>
	<brief_title>ADXS11-001 High Dose HPV+ Cervical Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Small Cell</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Adenosquamous</mesh_term>
	<criteria>Patients histologicallyconfirmed , persistent , metastatic recurrent squamous nonsquamous cell carcinoma , adenosquamous carcinoma , adenocarcinoma cervix document disease progression ( disease amenable surgery standard radiotherapy ) . Patients receive 1 prior cytotoxic treatment regimen . Subject may receive ≤2 prior regimen treatment metastatic disease . Subject able provide write informed consent . Subject must ECOG performance status 0 1 . In opinion investigator , subject rapidly progress disease , OR life expectancy le 6 month , OR would unable receive least one cycle therapy . Subject receive chemotherapy and/or radiation therapy ( except palliative radiation therapy diseaserelated pain ) within ≤2 week first ADXS11001 infusion . Subject know additional malignancy progress require active treatment . Exceptions include basal cell carcinoma skin , squamous cell carcinoma skin , situ cervical cancer undergone potentially curative therapy . Has contraindication administration trimethoprim/sulfamethoxazole ampicillin . Has implant medical device ( ) pose high risk colonization and/or easily remove ( e.g. , prosthetic joint , artificial heart valve , pacemaker , orthopedic screw ( ) , metal plate ( ) , bone graft ( ) , exogenous implant ( ) ) . NOTE : More common device prosthetics include arterial venous stent , dental breast implant , venous access device ( e.g. , PortaCath Mediport ) permit . Sponsor must contact prior consent subject device and/or implant .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Adenocarcinoma</keyword>
	<keyword>Carcinoma</keyword>
	<keyword>Carcinoma , Squamous Cell</keyword>
	<keyword>Uterine Cervical Neoplasms</keyword>
	<keyword>Small Cell Lung Carcinoma</keyword>
	<keyword>Carcinoma , Small Cell</keyword>
	<keyword>Carcinoma , Adenosquamous</keyword>
	<keyword>Neoplasms , Glandular Epithelial</keyword>
	<keyword>Neoplasms Histologic Type</keyword>
	<keyword>Neoplasms</keyword>
	<keyword>Neoplasms , Squamous Cell</keyword>
	<keyword>Uterine Neoplasms</keyword>
	<keyword>Genital Neoplasms , Female</keyword>
	<keyword>Urogenital Neoplasms</keyword>
	<keyword>Neoplasms Site</keyword>
	<keyword>Uterine Cervical Diseases</keyword>
	<keyword>Uterine Diseases</keyword>
	<keyword>Genital Diseases , Female</keyword>
</DOC>